09:17 AM EDT, 03/20/2025 (MT Newswires) -- Autonomix Medical ( AMIX ) shares were up more than 10% in recent premarket activity Thursday after the medical device company said the US Patent and Trademark Office had granted it a patent for its proprietary catheter-based technology used to collect and process sensing data for real-time physiological monitoring.

The company said the broad applications for the technology include heart mapping, arterial mapping, parenchymal monitoring, central nervous system monitoring, and implant, robotic and wearable precision applications.

Autonomix Medical ( AMIX ) said it expects to file an investigational device exemption with the US Food and Drug Administration.

The company also said it aims to begin US clinical trials this year in support of a labeling indication to commercialize the Autonomix Sensing and RF Ablation System in the US to treat pancreatic cancer pain.